Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Shanghai start-up Laekna gains exclusive license to Novartis prostate cancer compound CFG920

Executive Summary

Laekna Therapeutics Shanghai Co. Ltd. acquired exclusive global rights from Novartis Pharma AG to develop, manufacture, and commercialize its CFG920 (Laekna renamed LAE001) oral CYP17 inhibitor for prostate cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register